Project Grant R01AI184781
Award Date
6/11/25
Completion Date
5/31/30
Dollars Obligated
$464K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Texas, USA
Similar Awards
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $232,800 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to the University of Texas Medical Branch at Galveston (UTMB) to identify diagnostic biomarkers and develop a proof-of-concept immunoassay for typhus group rickettsioses (TGRs), which include epidemic typhus and murine typhus. The goal is to create an antigen-based diagnostic assay that can enable early detection and treatment of these...
This $232,500.00 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will fund research to investigate the antimicrobial properties of the Rickettsia buchneri endosymbiont found in the blacklegged tick Ixodes scapularis. The research aims to determine how R. buchneri regulates the expression of its putative antibiotic synthesis genes and toxin/antidote modules, and assess the...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $824,955.00 to Tufts University School of Medicine to conduct research on the immune response to tick-transmitted spotted fever group rickettsiae (SFGR). The primary objectives are to differentiate immune effector profiles in the skin after tick transmission of SFGR associated and not associated with spotted...
This $2,093,289 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to develop genetic engineering and axenic growth capabilities for the tick-borne bacterial pathogens Ehrlichia chaffeensis and Anaplasma phagocytophilum. The research aims to 1) optimize Himar1 mutagenesis to create a comprehensive E. chaffeensis genome mutation library, 2) expand targeted mutation...
This federal Project Grant award for $1,663,244.00 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant supports research to characterize innate immune signaling pathways in the tick Ixodes scapularis, which transmits Lyme and other emerging infectious diseases. The research aims to expand understanding of immune signaling in ticks, with the goal of identifying new interventions to...
This federal Project Grant award for $637,275 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to uncover the mechanisms behind how gram-negative bacterial pathogens rapidly develop tolerance to chemical stressors like antibiotics. The research aims to determine how bacteria can inhibit the functioning of existing porin proteins in their outer membrane within minutes of exposure to...
This federal Project Grant award in the amount of $800,624, provided by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research), aims to develop novel inhibitors of the enzyme thioredoxin glutathione reductase (TGR) for the treatment of schistosomiasis, a parasitic disease affecting over 200 million people worldwide. The key objectives are to optimize the potency, selectivity, and drug-like properties of TGR inhibitors through...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a Project Grant valued at $718,758 to the Texas Biomedical Research Institute under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant is focused on evaluating the use of IL-21-IgFc fusion protein as a host-directed immunotherapy to improve immune reconstitution and reduce the risk of latent tuberculosis (TB) reactivation in Mycobacterium tuberculosis (MTB) and simian immunodeficiency virus (SIV)...
This federal Project Grant award of $787,171 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to develop novel 1,2,4-triazole and pyrrolidine compounds as potential treatments for tuberculosis (TB). The primary objectives are to demonstrate preclinical proof-of-concept for these compound classes, optimize their pharmacological properties, and investigate their unique mechanism of action compared...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $299,995 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Xiretsa Inc., a minority-owned small business located in Santa Barbara, CA. The grant will fund the development of a novel class of antimicrobial compounds called Anti-Infective Conjugated Electrolytes (ACEs) that target the bacterial cell membrane to address the growing threat of antimicrobial resistance. The project...